The Food and Drug Administration (FDA), in its review of pharmaceuticals for safety and effectiveness, has relied heavily on placebo-controlled studies. In their prescribing practice, physicians often face clinical decisions between several FDA-approved drugs for the same indication, with little guidance from the FDA on the similarities or differences of the drugs. The public could benefit if the FDA were more proactive in declaring, when applicable, that the best available evidence does not indicate any significant clinical advantage for a particular FDA-approved drug compared with others.
Lasser KE, Allen PD, Woolhandler SJ, et al.Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
2.
Furberg CD, Psaty BM, Pahor M, et al.Clinical implications of recent findings from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) and other studies of hypertension. Ann Intern Med. 2001;135:1074-1078.
3.
Guidance for Industry:E 10 choice of control group and related issues in clinical trials. Available at: http://www.fda.gov/cder/guidancehindex.htm. Accessed October 27, 2002.
4.
Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CMAJ. 2002;166:616-623.
5.
Carpenter WT. From clinical trial to prescription. Arch Gen Psychiatry. 2002;59:282-285.
6.
Okie S, Kaufman M. Drug firm may not call Celebrex safer, FDA says: study did not back anti-arthritis drug claims. Washington Post. June 8, 2002:A2.
